Redirecting to https://medicaldialogues.in/news/industry/pharma/merck-daiichi-sankyo-withdraw-us-appication-for-patritumab-deruxtecan-for-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-149221